Introduction
Diarrhea is a principal cause of morbidity and mortality in children living in poverty in the developing world. Improved case management of acute dehydrating diarrhea through the use of oral rehydration therapy has increased the relative contribution of dysentery and persistent diarrhea as to the present day burden of diarrheal disease. Shigella is the enteric infection most consistently associated with the clinical dysentery syndrome [1], prolonged episodes of acute diarrhea, and the development of persistent diarrhea. Episodes of shigellosis may result in protein-losing enteropathy [2] and subsequent linear growth shortfalls in children [3] . Shigella is also an important cause of traveler's diarrhea and diarrhea in military units. Shigella dysenteriae 1 is the cause of large outbreaks of disease with high mortality rates in displaced persons [4] . These factors, taken together with the progressive emergence of antibiotic resistance to Shigella, have long made this organism a priority for vaccine development by the WHO through the initiative for vaccine research. This recent interest is complemen-ted by funding for vaccine development from the Bill & Melinda Gates Foundation. Funding in the basic sciences and pathogenesis remains strong as Shigella flexneri is one of the most studied pathogens and a key model organism used to understand the type III secretion apparatus [5 ] , intracellular persistence [6 ] , and antiapoptosis factors [7 ] .
Epidemiology
Shigellosis results from the exposure to low inoculums of S. dysenteriae, S. flexneri, Shigella boydii, and Shigella sonnei. In highly endemic areas, peak infection rates occur in the second year of life. Although there is evidence of protective immunity following natural infection, the existence of 46 serotypes, despite a measure of cross-reactivity between O-antigens, means that children routinely experience multiple episodes of shigellosis in early childhood in areas where transmission is intense.
Shigella has shown a poorly explained temporal procession in serogroup dominance. At the beginning of the 20th century, S. dysenteriae was the dominant group, in the 1930s and 1940s, S. flexneri replaced S. dysenteriae as the dominant serogroup in the absence of epidemics. Epidemiologic transition, seen first in Israel, Argentina, and now being described in Vietnam [8 ], has consistently favored the emergence of S. sonnei as the dominant serogroup, although the reason for this is not clear. In the USA, shigellosis appears to be decreasing in incidence. It is the third most frequent FoodNet pathogen in sentinel states with a population-based incidence of 3.99/100 000, but rates in 2009 were found to be significantly decreased from incidence rates between 1996 and 1998 [9 ] . It is unclear whether this represents a temporary dip in incidence or the beginning of a durable trend.
A very complete molecular investigation into the S. flexneri, initially described as variant serotype X (later termed 200217), was first described in 2001 but rapidly became the most prevalent serotype in eight of 11 provinces under surveillance in China, significantly added to our understanding of the dissemination and spread of isolates [10 ] . Full genome sequencing was done on one isolate and comparative genomics of extended multilocus sequence typing (MLST) on 37 serotype X variants and 74 isolates of other serotypes from provinces under surveillance, as well as reference strains 2457T, Sf301, and Sf8401. Sixty-nine of the 74 strains representing other serotypes also had the same MLST strain type, which was identical but distinct from reference strains 2457T, Sf301, and Sf8401. This work was complemented by pulsedfield gel electrophoresis (PFGE) analysis on 655 isolates from 11 provinces that demonstrated 154 pulse types, 24 of which were displayed by more than one serotype. One pulse type described over 30% of these isolates. The interpretation of this extensive investigation, which employed a variety of techniques that allow for the view of the epidemic to occur through a variety of lenses, is that the predominant sequence type (ST91 represented by 200 217) has been circulating in China prior to its recognition. For reasons that are not clear, it rapidly expanded and underwent multiple serotype switching events and acquired the resistance to multiple antibiotics during its spread. The importance of this finding is not to be understated -generally serotypes are used as markers of clonality (not sensitive ones, but markers nonetheless).
That assumption would clearly be in error in this epidemic -serotype switching was well documented (an estimate of >30 such events occurred) and allowed the spread of this new distinct strain. Furthermore, the careful documentation of this switching has sobering implications for vaccine development, as the foundation of the success of a vaccine based on O-antigens requires the temporal stability of principal serotypes (assuming the vaccine is polyvalent, as is generally considered to be a prerequisite).
Pathogenesis
The detailed understanding of the more than 30 effectors of the type III secretion system continues to be expanded upon and clarified [5 ,6 ,11] , and a key mechanism of host recognition of organisms with type III secretion systems was elucidated [12 ] . Recently, the understanding of the host-pathogen interaction has included a greater study of factors that decrease intestinal-epithelial turnover through antiapoptotic factors such as the soluble form of pilus protein FimA [7 ] and basement membrane adherence, mediated by OspE [13 ] . The interaction of the host defenses and Shigella pathogenesis is also an area of expanded activity [14 ] , including the demonstration of enhanced epithelial infection of S. flexneri upon interaction with factors liberated during neutrophil degranulation [15 ] , the downregulation of the host immune system via OspB and OspF's interaction with the retinoblastoma protein [16 ], and IpaH9.8s downregulation of nuclear factor-kappaB (NF-kB)-mediated immune response [17] . Additional important contributions included a human explant model for the study of early steps in Shigella infection [18 ] and a fluorescence microscopic technique to allow for the evaluation of intracellular vacuole trafficking and activity [19 ] , both of which will be useful platforms to expand our understanding of host-pathogen interactions.
Treatment
The progressive development of antibiotic resistance in Shigella isolates is not new. Ampicillin and trimethoprimsulfamethoxazole, once affordable mainstays of therapy, have long ago lost efficacy in most Shigella endemic regions. Nalidixic acid was an alternative for a brief period, only as resistance rapidly developed in Asia. Ciprofloxacin was a highly effective alternative, despite the reservations of its use in children, but Shigella resistant to ciprofloxacin is increasingly common in India and in travelers returning from India [20] , and a recent report from Bangalore, India, described an increase of resistance from 0 to 48% in a 5-year period between 2002 and 2007 [21 ] . Fluoroquinolone-resistant strains from the region were found to have mutations in gyrA and parC and had developed an active efflux system [22 ] . Ceftriaxone offers an alternative, but Shigella resistant to ceftriaxone has been reported from India [23] and Vietnam [24 ] and that resistance to azithromycin has also been reported [25 ] .
Clearly, with these recent descriptions, regional antibiotic susceptibility patterns have to be given greater importance in order to ensure adequate case management. The adequate dissemination of this information to relevant providers who are often nonphysicians (nurses, pharmacists, and healthcare workers) in impoverished areas is a frequently overlooked step in the implementation of effective antibiotic therapy. At a regional or national level, antibiotic recommendations for Shigella and dysentery (treatment for dysentery in cases in which stool culture is not available should be targeted at Shigella) should be adapted centrally and likely input into the integrated management of childhood-illness treatment protocol. In the absence of local data, the recommendations from the WHO should be followed [26] . A recent review of the efficacy of this treatment was estimated at 99%, although the emergence of new more resistant strains since the time that the studies included in this retrospective analysis were performed suggests that this estimate overestimates the efficacy, particularly in south-east Asia [27 ] . First-line therapy is ciprofloxacin (in all age groups, including pediatrics) and second-line is pivmecillinam (where available), ceftriaxone, or azithromycin. Azithromycin has the added advantage of also treating most isolates of Campylobacter, a second major cause of dysenteric diarrhea in children under the age of 2 years [28] . Children under the age of 5 years in endemic areas should also receive zinc 10 mg/day if 0-6 months of age and 20 mg/day for children over the age of 6 months. Treatment aimed at cases in nonendemic areas has also recently been reviewed and is similar, although azithromycin was favored as the firstline treatment in children [29 ] .
Nutritional therapy is also warranted in shigellosis. The relationship between undernutrition and shigellosis is strong -undernutrition significantly increases the incidence of shigellosis and is also associated with more severe disease [28, 30 ] . In endemic areas, nutritional therapy should be considered as adjunct therapy that is guided by the treatment team. In a recent Venezuelan study [31 ] of children recovering from persistent diarrhea in which Shigella was one of the principal underlying etiologies, a trial of isocaloric feeds with yogurt and green bananas showed increased weight gain and decreased diarrheal duration in the green-plantain group. This work was complemented by a clinical trial of green bananas as adjunctive therapy in male children with Shigella and dysentery [32 ] . All children received ciprofloxacin, and children receiving green bananas had an increased percentage of clinical cure at day 5 from 67 to 85%, decreased stool myeloperoxidase activity at day 5, and decreased number of stools/day starting 3 days following the initiation of therapy. Green bananas are widely available and affordable in endemic areas of Asia, Africa, and South America where shigellosis is endemic. The evidence would now support their specific recommendation in the management of children over the age of 6 months in endemic areas where they are available. This is the only recent good news in Shigella therapy at a time when antibiotic resistance is threatening currently recommended treatment strategies.
Postinfectious complications
There was a recent growing interest in the postinfectious complications of shigellosis including reactive arthritis [33 ,34] and postinfectious irritable bowel syndrome (IBS) [35 ] . Reactive arthritis is the common term to the inflammatory sequelae following infection with Shigella, Campylobacter, Salmonella, Yersinia, or Chlamydia (see [36 ] for recent review). Although there is evidence that these infections are associated with a spondyloarthropathy, particularly severe in HLAB27þ individuals, there is no precise definition of the disease, which may include arthritis (predominantly in the joints of the lower extremities), enthesopathy, inflammatory lower back pain, dactylitis, and less frequently urethritis and conjunctivitis. The criteria derived from the 1995 International Workshop on Reactive Arthritis [37] are considered inadequate by many authors, and there is a general consensus that improvements are needed. Beyond the lack of a clear clinical or laboratory parameter for case definition is the small number of studies done in USA and European populations, not in populations in which the disease is endemic. Regardless of definition, there is clear evidence that a small portion of individuals with dysentery do go on to develop a chronic progressive spondyloarthropathy, the management of which is classically challenging if it does not respond to first-line nonsteroidal anti-inflammatory agents or second-line disease modifying agents such as methotrexate or azathioprine. There is some anecdotal evidence of the successful use of infliximab in the treatment of chronic reactive arthritis resistant to these therapies, although results from randomized clinical trials are not available [38] . The rising interest in arthritis following natural infections with Shigella was sufficient to trigger the assembly of an expert panel to analyze this possible adverse effect with the development of Shigella vaccines under development [34] . It was concluded that the risk was likely offset by disease burden reduction in highly endemic areas, but called for phase I patients to be screened for HLA-B27 and excluded if positive. Additionally, the panel concluded that future phase 2 and phase 3 trials have follow-on surveillance to evaluate the incidence of reactive arthritis.
In a recent case-control study of children in Italy [39] with diarrhea caused by Salmonella, Shigella, or Campylobacter, there was a significant association with these bacteria and the development of a gastrointestinal disorder in 87% cases significant with IBS case definitions. Remarkably, 43% (six of 14) of children with prior Shigella infections were found to have symptoms of postinfectious gastrointestinal disease, whereas symptoms were present in only 11% of controls. Haagsma et al. [35 ] published a report of postinfectious inflammatory bowel syndrome developing in 9% of patients with prior Campylobacter, Salmonella, or Shigella infections in the Netherlands. Despite the differences in patient populations and prevalence, both suggest that lasting effects of shigellosis occur frequently following invasive diarrhea in the developed world.
Developments in Shigella vaccines
The increased investment in Shigella vaccines has stimulated the development of candidate vaccines from multiple groups. Predominant among new candidates are polysaccharide conjugates, synthetic conjugates, invasion complex-based, and live attenuated vaccines (recently reviewed in [40 ,41] ).
Despite a thorough understanding of Shigella O-antigen structure [42] and improved techniques for enhancing immunogenicity of the polysaccharide unit, there was disappointing news from a field trial of Shigella conjugates in a pediatric population in Israel [43 ] . This trial included the evaluation of both S. sonnei conjugate and S. flexneri 2a conjugate vaccines. The S. sonnei conjugate had no efficacy in 1-2-year-old children, the key age group infected in highly endemic areas, whereas the vaccine demonstrated an efficacy of 71.1% in 3-4-year-olds. The S. flexneri results were limited by the occurrence of only seven documented cases of S. flexneri 2a infection in 1315 children, so no efficacy information could be obtained. It is hoped that improved techniques for enhancing immugenicity of the polysaccharide unit will bring improved protection to the most relevant age groups [44 ] . Synthetic conjugates allow for improved standardization and avoid the risk of lipopolysaccharide (LPS) contamination and a synthetic S. flexneri 2a conjugate has recently shown immunogenicity in mice and offers an alternate strategy [45 ] , albeit in very early stages of development. Similarly advances are being made in the purification and evaluation of candidates from major outer membrane proteins (MOMPs) of S. flexneri 2a, which is an important development offering the hope of a candidate which is more likely to be cross-reactive [46 ] . Invasin-complex-based vaccines (Invaplex), a purified extract of S. flexneri 2a containing LPS including IpaB and IpaC, are an alternative approach that has also demonstrated immugenicity in early trials [47] . Lastly, a second-generation virG(iscA) S. sonnei live attenuated candidate vaccine more highly attenuated via the loss of ShET-1, ShET-2, and MsbB2 (which makes the lipid A portion of LPS less endotoxic) has been shown to be immunogenic in guinea pigs and is hoped to be less reactogenic when moved forward into human trials [48] .
These advances are important, but are far from what is needed to adequately protect communities from shigellosis in the developing world. For example, in a highly endemic area in Peru where the incidence of shigellosis is 0.34 episodes per child-year [28] in children under the age of 5, a vaccine that conferred complete protection against S. flexneri 2a would prevent 34.3% of the cases of S. flexneri, but only 22.3% of the cases of Shigella. Alternatively, a vaccine conferring 100% efficacy in S. flexneri 2a, 3a, and 6 would protect children against 72.6% of the incident cases of shigellosis caused by S. flexneri, but only 47.5% of all cases of shigellosis. Clearly, we are still far from a vaccine offering coverage that would have a major impact on shigellosis burden in children in the developing world.
Conclusion
In the near future, the key measures to control the burden of disease from shigellosis will be improved access to water and sanitation, access to education for women, and the control of undernutrition in children in endemic areas. Improved case management is also critical and should include regional monitoring of antibiotic resistance and the inclusion of treatment flowcharts with specific antimicrobials that have been demonstrated to be effective in vitro in the region. This information must be included into management guidelines (such as the integrated management of childhood illness) available to local clinicians and nonclinician attendants (nurses, pharmacists, and healthcare workers) in endemic areas. Adjuvant therapy with nutritional supplementation following shigellosis, or dysentery, should include nutritional therapy, including zinc. In areas where green bananas are available, caregivers should be encouraged to include them as a staple in the treatment and early rehabilitation period. A study that collected around 300 Shigella isolates in three discrete studies over a 14-year period between 1995 and 2008 showed a switch in the predominant serogroup (from S. flexneri to S. sonnei). In the latest period under study, 23% of strains were resistant to ceftriaxone and 68% were resistant to nalidixic acid. Persistent diarrhea is notably resistant to specific treatment interventions, responding to nutritional interventions (such as zinc supplementation) to a greater extent than to medical therapy. This trial that compared isocaloric diets of green plantains and yogurt in persistent diarrhea in hospitalized children found that children receiving the green plantains had shorter durations of diarrhea and improved weight gain at a total lower cost. Shigella was one of the principal identified pathogens in participants.
